APTOF · As filed with the SEC
Aptose Biosciences balance sheet, by fiscal year
The statement as Aptose Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Financial Position · USD
| USD | FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 |
|---|---|---|---|---|
| Current assets: | ||||
| Cash and cash equivalents | 935,000 | 6,152,000 | 9,252,000 | 36,970,000 |
| Investments | — | — | — | 9,989,000 |
| Restricted cash equivalents, current | — | 555,000 | — | — |
| Restricted cash and restricted cash equivalents | 3,161,000 | — | — | — |
| Prepaid expenses | 2,209,000 | 2,253,000 | 2,042,000 | 2,303,000 |
| Other current assets | 141,000 | 570,000 | 600,000 | 257,000 |
| Total current assets | 6,446,000 | 9,530,000 | 11,894,000 | 49,519,000 |
| Non-current assets: | ||||
| Property and equipment, net | 4,000 | 26,000 | 152,000 | 211,000 |
| Right-of-use assets, operating leases | 175,000 | 571,000 | 943,000 | 1,297,000 |
| Other long-term assets | 3,387,000 | — | — | — |
| Total non-current assets | 3,566,000 | 597,000 | 1,095,000 | 1,508,000 |
| Total assets | 10,012,000 | 10,127,000 | 12,989,000 | 51,027,000 |
| Current liabilities: | ||||
| Accounts payable to related parties | — | 0 | 2,554,000 | — |
| Accounts payable | 2,911,000 | 1,258,000 | 3,492,000 | 6,326,000 |
| Accrued liabilities | 6,202,000 | 2,773,000 | 8,829,000 | 5,657,000 |
| Current portion of lease liability, operating leases | 193,000 | 428,000 | 394,000 | 301,000 |
| Total current liabilities | 9,306,000 | 4,459,000 | 15,269,000 | 12,284,000 |
| Non-current liabilities: | ||||
| Lease liability, operating leases | 0 | 193,000 | 621,000 | 1,002,000 |
| Loan payable to related party | — | 10,018,000 | — | — |
| Loan payable to related party | 27,018,000 | — | — | — |
| Interest on related party loan payable | 855,000 | — | — | — |
| Total non-current liabilities | 27,873,000 | 10,211,000 | — | — |
| Total liabilities | 37,179,000 | 14,670,000 | 15,890,000 | 13,286,000 |
| Shareholders' deficit: | ||||
| Common shares, no par value, unlimited authorized shares, 2,552,429 and 2,006,028 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 459,771,000 | 457,404,000 | 444,806,000 | 437,520,000 |
| Additional paid-in capital | 83,813,000 | 83,336,000 | 72,146,000 | 68,869,000 |
| Accumulated other comprehensive loss | (4,316,000) | (4,316,000) | (4,316,000) | (4,318,000) |
| Accumulated deficit | (566,435,000) | (540,967,000) | (515,537,000) | (464,330,000) |
| Total shareholders' deficit | (27,167,000) | (4,543,000) | (2,901,000) | 37,741,000 |
| Total liabilities and shareholders' deficit | 10,012,000 | 10,127,000 | 12,989,000 | 51,027,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.